Drug search by name

Hemangeol and PVD

Result of checking the interaction of drug Hemangeol and disease PVD for safety when used together.

Check result:

Hemangeol <> PVD

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Due to their negative inotropic and chronotropic effects on the heart, beta-adrenergic receptor blocking agents (aka beta-blockers) reduce cardiac output and may precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. In addition, the nonselective beta-blockers (e.g., propranolol, pindolol, timolol) may attenuate catecholamine-mediated vasodilation during exercise by blocking beta-2 receptors in peripheral vessels. Therapy with beta-blockers should be administered cautiously in patients with peripheral vascular disease. Close monitoring for progression of arterial obstruction is advised.

References:

"Product Information. Cartrol (carteolol)." Abbott Pharmaceutical, Abbott Park, IL.
Coppeto JR "Transient ischemic attacks and amaurosis fugax from timolol." Ann Ophthalmol 17 (1985): 64-5
Broeder CE, Thomas EL, Martin NB, Hofman Z, Jesek JK, Scruggs KD, Wambsgans KC, Wilmore JH "Effects of propranolol and pindolol on cardiac output during extended periods of low-intensity physical activity." Am J Cardiol 72 (1993): 1188-95
Michelson EL, Frishman WH, Lewis JE, et al "Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension." Am J Med Oct 17 (1983): 68-80
"Product Information. Trandate (labetalol)." Glaxo Wellcome, Research Triangle Park, NC.
"Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals, East Hanover, NJ.
Breckenridge A, Roberts DH "Antihypertensive treatment in concomitant peripheral vascular disease: current experience and the potential of carvedilol." J Cardiovasc Pharmacol 18 Suppl 4 (1991): s78-81
"Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Lepantalo M "Beta blockade and intermittent claudication." Acta Med Scand 700 (1985): 1-48
"Product Information. Kerlone (betaxolol)." Searle, Skokie, IL.
Mashford ML, Coventry D, Hecker R, et al. "Adverse Drug Reactions Advisory Committee: ADRAC report for 1980." Med J Aust 1 (1982): 416-9
"Product Information. Zebeta (bisoprolol)." Lederle Laboratories, Wayne, NJ.
Eliasson K, Lins L-E, Sundqvist K "Peripheral vasospasm during beta-receptor blockade: a comparison between metoprolol and pindolol." Acta Med Scand 665 (1982): 109-12
"Product Information. Blocadren (timolol)." Merck & Co, Inc, West Point, PA.
"Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
"Product Information. Levatol (penbutolol)." Reed and Carnrick, Jersey City, NJ.
Eliasson K, Danielson M, Hylander B, Lindblad LE "Raynaud's phenomenon caused by beta-receptor blocking drugs." Acta Med Scand 215 (1984): 333-9
"Product Information. Normodyne (labetalol)." Schering Laboratories, Kenilworth, NJ.
"Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.
Holti G "A double-blind study of the peripheral vasoconstrictor effects of the beta-blocking drug penbutolol in patients with Raynaud's phenomenon." Curr Med Res Opin 6 (1979): 267-70
"Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.
"Product Information. Corgard (nadolol)." Bristol-Myers Squibb, Princeton, NJ.
Tcherdakoff P "Side-effects with long-term labetalol: an open study of 251 patients in a single centre." Pharmatherapeutica 3 (1983): 342-8
Myers J, Morgan T, Waga S, et al "Long-term experiences with labetalol." Med J Aust 1 (1980): 665-6
"Product Information. Betapace (sotalol)." Berlex, Richmond, CA.